HIV treatment is now highly effective and modern HCV drugs (DAAs) cure more than 95% people.
The information in this guide should help you feel more in control of some of the treatment choices. This includes the current difficulty of getting access to DAAs.
This should help you can focus on other things you want to do in life.
The 2017 edition of this guide has been updated throughout. This PDF version contains the final text as some web pages still need to be updated.
Download and view PDF – (700 Kb)
- What is hepatitis?
- What should I do first after a hepatitis C diagnosis?
- Are people around me now at risk?
- Hepatitis A and B
- Acute infection – chronic infection – end stage liver disease
- HIV and HCV coinfection
- What does your liver do?
- How does HCV damage your liver?
- How can you protect your liver?
- Risk of HCV progression in HIV positive people
- Tests to diagnose HCV
- Tests to monitor HCV
- HCV genotype and subtype
- Liver enzyme tests
- Screening for liver cancer in people with cirrhosis
- Measuring liver stiffness (FibroScan) and biomarkers
- Liver biopsy – now rarely needed
- Currently approved DAAs
- Who needs HCV treatment?
- How is HCV treated: direct acting antivirals (DAAs)
- Goals of HCV treatment
- Predicting the response to treatment
- HIV and HCV treatment for people with coinfection
- How response to HCV treatment is measured
- Drug interactions between HCV and HIV meds
- HCV treatment and drug users (IDUs)
- Retreating HCV
- Management of cirrhosis
- Liver transplant in people with HIV/HCV coinfection
- Depression, anxiety, and other psychiatric side effects – with old HCV drugs
- Flu-like symptoms, weight loss and fatigue – with old HCV drugs
- Anaemia, neutropenia and thrombocytopenia – with old HCV drugs
- Other side effects – with old HCV drugs
- Liver toxicity and HIV drugs
Credits and disclaimer
Thanks to doctors in the medical advisory group: Sanjay Bhagani, Duncan Churchill, Ed Ong, Alison Rodger and Chris Taylor.
Also to the community advisory group: Támas Bereczky, Polly Clayden, Giulio Maria Corbelli, Marc Ennals, Juanse Hernandez, Robert James, Maxime Journiac, Luís Mendão, Gemma Peppé, David Stuart, Kate Thomson and Miguel Vázquez for review comments and to Beth Higgins for drawings.
People living with HIV and HCV are included in the review group and have provided additional contributions and comments.
Thanks to the Monument Trust for continued financial support.
Cover design and original layout of print edition by No Days Off. Produced by HIV i-Base.
Disclaimer: information in this booklet is not intended to replace information from your doctor. Decisions relating to treatment should always be taken in consultation with your doctor.
Information about how we produced this guide and the importance of using language that is direct and easy to understand.
This includes information on how to write non technical medical information that may be useful as a resource for other organisations.
30 April 2017